Q3 2026 Insulet Corporation Earnings Call - INSULET CORP

Financial Performance:

• Third-quarter 2026 revenue reached $842 million, a 19.2% year-over-year increase on a reported basis and 19.6% on a constant currency basis.
• U.S. revenue grew 14.7%, while international revenue surged 33% (31.7% reported), driven by volume and favorable price mix.
• Adjusted gross margin expanded 200 basis points to 74.2%, and adjusted operating margin expanded 490 basis points to 22%.
• Adjusted EPS rose 60% to $1.99, significantly outpacing revenue growth.
• Free cash flow for the year-to-date was $212 million; full-year 2026 free cash flow is expected to be approximately $275 million.
• Company ended the quarter with $584 million in cash and investments, with full access to a $750 million revolving credit facility.
• Net interest expense was $12.1 million, and the adjusted tax rate was 20.2%.
• The customer base grew over 20% year-over-year, exceeding 600,000 global customers.

Guidance and Future Outlook:

• Full-year 2026 constant currency revenue growth guidance narrowed to the top end: 21–22% for the total company and 21.5–22.5% for Omnipod.
• Q4 2026 revenue growth is expected to be 13.5–17% (total company) and 13–16.5% (Omnipod).
• For 2027, growth is expected to moderate to "modestly below the mid-teens" (previously high-teens/mid-teens framework), reflecting a stronger base, new competition, and reduced international price/mix benefits.
• U.S. 2027 guidance is expected to land at the lower end of the prior framework (9–14%), while international growth is expected to moderate meaningfully from current levels.
• Management anticipates the 2026 revenue growth to be the 11th consecutive year of 20%+ growth, with EPS expected to grow >30% for 2026.
• 2027 outlook remains confident regarding top-tier growth and expanded profitability despite the moderating growth rate.

Business Segments and Product Lines:

• Omnipod 6: Second and final 510(k) submitted; expected launch in 2027 with features including 40% fewer boluses and 76% time in range (TIR) based on early data.
• Closed-Loop for Type 2: Pivotal "Evolution 3" study enrollment completed; 510(k) submission targeted for 2027 with a 2028 launch expectation.
• Omnipod Discover: Full U.S. market release achieved in October; over 35,000 users and 5,000 clinicians adopted, showing improved engagement and retention.
• Integration: Expanded Freestyle Libre 3 Plus integration to 10 new markets; U.S. iOS launch expected in Q4 2026.
• Sales Force: Completed second U.S. Salesforce expansion, increasing footprint by 25%; implemented first new CRM platform in a decade.
• Type 2 Action Plan: Implemented stricter sampling governance, added clinical retention specialists, and tied sales compensation to retention; early signs of improved retention observed.

Market and Competitive Landscape:

• Insulet maintains a dominant market position, capturing over 85% of new customer starts from Manual Insulin (MDI) to Automated Insulin Delivery (AID).
• Omnipod is the number one AID choice among providers and patients; brand awareness is high (67% in U.S., 84% in UK, 74% in Canada).
• Management views the AID market as under-penetrated relative to CGM, with a large Total Addressable Market (TAM) including Type 1 and Type 2 patients.
• Acknowledges increased competition in 2027 but emphasizes Insulet's scale, manufacturing capacity, and data moat as protective factors.
• PBM contract negotiations for 2027 are 33% complete; one finalized, two expected to be finalized shortly, with stable pricing expected across the sector.
• International expansion includes a recent launch in Spain and 17 new markets in 2026, reaching 20 total markets with Omnipod 5.

Risks and Challenges:

• 2027 Growth Moderation: Anticipated slowdown due to tougher comparable years, reduced international price-mix benefits, and the entry of new competitors.
• Competition: New competitive products entering the market are expected to impact new customer share, though Insulet plans to retain the majority.
• Type 2 Retention: Previously noted attrition challenges; while improving, management expects a gradual build-up of retention benefits rather than immediate impact.
• Regulatory/Supply: Dependence on timely 510(k) approvals for Omnipod 6 and Type 2 closed-loop systems; supply chain resiliency remains a focus.
• GLP-1 Impact: No observed negative impact from GLP-1 drug usage on Type 2 new customer starts; GLP-1s viewed as complementary.

Management Commentary and Tone:

• Tone is highly confident, describing the quarter as "strong" and reiterating commitment to the "11th consecutive year of 20%+ growth."
• Management expressed clear-eyed realism regarding the 2027 outlook, explicitly choosing a "conservative approach" to guidance to account for competition and base size.
• Emphasized "maniacal focus" on patient outcomes and the strength of the Omnipod ecosystem (hardware, software, and data).
• Highlighted the strategic shift from pure hardware growth to a "flywheel" of innovation, data, and patient engagement via Omnipod Discover.
• Reaffirmed the board's confidence through a $1 billion increase in share repurchase authorization, with $400 million planned for Q4.

Analyst Questions and Answers:

• 2027 Conservatism: Management clarified the 2027 outlook is driven by three factors: a stronger 2026 base, the pacing of innovation (Omnipod 6 launch), and the competitive landscape; not just a generic conservative bias.
• Type 2 Retention: Analysts asked for specific attrition rates; management confirmed Type 1 attrition remains ~10%, while Type 2 attrition (previously 25-30%) showed modest improvement in Q3 due to new action plans.
• PBM Strategy: Confirmed that while new competitors are disciplined on pricing, Insulet maintains >98% coverage and a strategy of broad access with stable pricing expected in 2027.
• Q4 Revenue vs. Installed Base: Explained the discrepancy between high-teens installed base growth and single-digit/low-double-digit Q4 revenue guidance is due to a large year-over-year comparison (comp) in Q4.
• Omnipod 6 Features: Reiterated focus on "lifestyle fit," 40% reduction in boluses, phone control, and sensor connectivity as key differentiators for the 2027 launch.
• EPS Growth: Confirmed confidence in the previously stated goal of >20% EPS growth over the 2027 horizon, despite not providing a specific number today.

Other Key Points:

• Manufacturing Scale: Highlighted ability to produce tens of millions of pods annually with facilities in Acton, Malaysia, and upcoming sites in Costa Rica, creating a significant competitive moat against new entrants.
• Data Advantage: Omnipod processes over 850 million data messages daily, enabling the Omnipod Discover platform to provide personalized insights that drive engagement.
• Capital Allocation: $400 million share repurchase in Q4 funded by cash on hand; revolver upsized to $750 million; Term Loan B refinanced to reduce rates.
• Strategic Priorities: Three core pillars identified: strengthening commercial capabilities (sales force, CRM), accelerating innovation (Omnipod 6, Type 2 closed-loop), and expanding access (PBM contracts, international launches).